Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Bioequivalence Study of Paracetamol With Oral Single Dose Administration in Healthy Adult Subjects Under Fasting Conditions

← catalyst calendar

NCT06855576 · results posted

Sponsored by HALEON (industry) · HLN — their whole pipeline →.

Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Other
Enrollment
54actual
Sites
1
Country
Germany

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-03-05actualWhen the study began enrolling
Primary completion2025-04-17actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-04-17actualThe whole study's end, after follow-up
First posted2025-03-04actualWhen this record first appeared on the registry
Results posted2026-07-01actualWhen the sponsor posted results to the registry
Record updated2026-07-01actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Fever
  • Pain

Interventions

  • Drug: Paracetamol ODT
  • Drug: Alvedon film-coated tablet
  • Drug: Panadol film-coated Tablet

Primary outcomes

what the primary-completion date above is the date OF
Maximum Observed Concentration (Cmax) for Paracetamol ODT (Test) Versus (vs.) Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
measured Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Area Under the Concentration vs. Time Curve From Dosing Time to the Last Measurement Time Point (AUC0-tlast) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
measured Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Time to Reach Maximum Concentration (Tmax) for Paracetamol ODT (Test) vs. Paracetamol (Alvedon Film-coated Tablet) (Reference 1)
measured Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Cmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)
measured Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
AUC0-tlast for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)
measured Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period
Tmax for Paracetamol ODT (Test) vs. Paracetamol (Panadol Film-coated Tablet) (Reference 2)
measured Within one hour prior to dosing, at 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 150, 180 minutes and at 4, 5, 6, 8, 10, 12, 14, 16 and 24 hours following dosing in each treatment period

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-05-07 · 994 KB · Prot_000.pdf
Statistical Analysis Planposted 2025-03-28 · 4.2 MB · SAP_001.pdf

Permalink · HLN's whole pipeline · Catalyst calendar · Every registered study · What changed